Read news as it happens
Create a Rediffmail account
Subscribe via RSS
After 15 years, Ranjit Shahani steps down as Novartis' India chief
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in......
Why price cap on drugs is counter productive
To ensure equal access to health care, the government must consider it in a holistic manner and improve all parameters, says Ranjit Shahani. India is the fourth fastest growing economy in......
Novartis has 219 patents in India
India’s intent to respect intellectual property may have drawn international criticism following the Supreme Court’s decision on Glivec, but facts point at a different story.After Swiss......
Indian pharma has no incentive to innovate
No one expected, when the first major clinical trial started on Glivec in 2000, that the patients would live much beyond a couple of years.Yet, seven years later, 86 per cent of them were still......
SC decision on Novartis to benefit poor: Pharma cos
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic......
bharatiya janata party
united progressive alliance
national democratic alliance
rashtriya swayamsevak sangh
central bureau of investigation
Top Coverage News
US Presidential Elections 2016
Coming to India and making
Success in manufacturing is not just about being cheap - cheap labour, cheap land, cheap power...
India, through the eye of a camera
Commonwealth Games - 2014
The defence coverage of Rediff.com
Office email App
© 2018 Rediff.com